Plaquenil retinal screening: what every prescriber should know

Hydroxychloroquine — better known by the brand name Plaquenil — is one of the most prescribed disease-modifying drugs in rheumatology. It’s affordable, well tolerated, and genuinely life-changing for patients with lupus, rheumatoid arthritis, and other autoimmune conditions. But it carries a quiet, serious risk: it can damage the retina, and that damage is irreversible and often silent until vision is already lost.

That combination — a common drug, a preventable harm, and a window where intervention still matters — is exactly why retinal monitoring isn’t optional. The good news for prescribers is that compliant monitoring no longer requires sending every patient across town to an ophthalmologist.

Why hydroxychloroquine requires retinal monitoring

HCQ can accumulate in the retinal pigment epithelium and cause a progressive maculopathy. The clinical problem is timing: by the time a patient notices a paracentral scotoma, trouble reading, or color changes, the toxicity is typically advanced — and stopping the drug won’t reverse what’s already gone. Worse, damage can continue to progress even after the medication is discontinued.

Screening exists to catch retinal changes before they reach that point, while the prescriber still has a decision to make.

• Early toxicity is frequently asymptomatic
• Damage is permanent and can advance after cessation
• Detection requires imaging or functional testing, not a symptom check
• The patient population is often on the drug for years or decades

Who is on Plaquenil — and who’s at higher risk

The prescribing footprint is broad. Patients on hydroxychloroquine commonly include those with:

• Systemic lupus erythematosus (SLE)
• Rheumatoid arthritis
• Sjögren’s syndrome and other connective-tissue disease
• Various off-label autoimmune and dermatologic indications

Within that group, certain factors are generally associated with elevated retinal risk — including longer duration of therapy, higher daily dose relative to body weight, kidney disease, concurrent tamoxifen use, and pre-existing retinal or macular disease. Risk stratification matters, but it doesn’t replace baseline and ongoing screening.

The patient on Plaquenil rarely complains about their eyes. That’s precisely why someone has to look — on a schedule, not on symptoms.

What the guidelines generally call for

This article is general education, not a dosing or treatment protocol — clinicians should follow current American Academy of Ophthalmology (AAO) guidance and apply their own judgment. That said, the broad monitoring framework is consistent and worth understanding:

• A baseline examination at or near the start of therapy to document retinal status and identify pre-existing disease
• Ongoing screening that typically begins after a defined period of use and then continues at regular intervals, with more frequent monitoring for higher-risk patients
• Use of objective, sensitive testing (such as automated visual fields and structural retinal imaging) rather than relying on patient-reported symptoms

The specifics — daily-dose thresholds, the year therapy is considered higher risk, and recommended testing modalities — are defined by the AAO and updated periodically. Prescribers don’t need to memorize every detail. They need a reliable way to make sure the screening actually happens.

Where monitoring actually breaks down

In practice, the gap is logistical, not clinical. A rheumatologist or primary care prescriber knows the patient needs screening, refers out, and then the referral evaporates — the patient doesn’t schedule, can’t get an ophthalmology appointment for months, or simply never goes. The prescriber is left managing a drug with a known retinal risk and no current eye data.

This is the same problem teleophthalmology solves elsewhere: the imaging and the interpretation don’t have to happen in the same place.

How in-house imaging plus remote reading makes compliance easy

EyeSee Services is a remote ophthalmology reading service — think radiology, but for eyes. Your practice captures a retinal image with your own camera during a visit the patient is already attending, uploads it, and a board-certified ophthalmologist interprets it. A structured report comes back, typically in 24–48 hours.

For a Plaquenil monitoring program, that changes the math:

• Screening happens in your clinic, on your schedule, at the visit you already have
• The patient doesn’t get lost in a referral that may never close
• You receive a documented specialist read for the chart and for compliance
• The patient relationship stays entirely with your practice

EyeSee doesn’t sell cameras and doesn’t take over the patient — the exam stays with you. We provide the expert interpretation your practice doesn’t have on staff. See our dedicated Plaquenil monitoring overview for how a program fits into existing workflows, and review how it works end to end.

Does this replace the patient’s eye specialist?

No. EyeSee provides the screening interpretation and a report; any findings that warrant further evaluation or treatment are referred for in-person ophthalmologic care. The goal is to make sure routine monitoring reliably gets done — and to flag the cases that need more.

What does the prescriber actually have to do?

Capture the image during the visit and upload it. The clinical decisions — continuing, adjusting, or referring — remain yours, informed by the report and current guidelines.

Build the safety net into the visit you already have

Patients trust prescribers to manage the risks of the medications they take. With hydroxychloroquine, that responsibility includes making sure the retina is being watched. The practices that do this best don’t rely on referrals to close themselves — they bring the screening in-house and let a specialist read it remotely.

Ready to make Plaquenil monitoring something that actually happens for every patient? Schedule a demo or explore our Plaquenil monitoring program.